Health Bulletin 29/December/2021

Published On 2021-12-29 12:38 GMT   |   Update On 2021-12-29 12:38 GMT
Advertisement

Here are Top Health stories of the day

Resident doctors to continue stir as talks with Mandaviya fail

Resident doctors in Delhi, who have been protesting over the delay in NEET-PG 2021 counselling for the past 12 days, on Tuesday decided to continue the stir, as a meeting between their federation's delegation and the Union health minister failed to make any headway.

The meeting between a delegation of the Federation of Resident Doctors' Association (FORDA) and Union Health Minister Mansukh Mandaviya took place at Nirman Bhawan here, but the doctors' body said, the "response was not satisfactory".

Advertisement

For more details, check out the full story on the link below:

Resident Doctors To Continue Stir As Talks With Mandaviya Fail


MCC NEET counselling 2021


Mediclaim cannot be rejected citing existing illness: SC

An insurer cannot repudiate a claim by citing an existing medical condition that was disclosed by the insured in the proposal form, once the policy has been issued, the Supreme Court has said.

A bench of justices D Y Chandrachud and B V Nagarathna also said a proposer is under a duty to disclose to the insurer all material facts within his knowledge.

For more details, check out the full story on the link below:

Mediclaim Cannot Be Rejected Citing Existing Illness: SC


Granules India secures USFDA nod for Prazosin Hydrochloride Capsules

Granules India Limited announced that the US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of Granules India Limited, for Prazosin Hydrochloride Capsules, USP 1mg, 2mg & 5mg.

It is bioequivalent to the reference listed drug product (RLD), Mini plus capsules 1Mg, 2Mg & 5 Mg of Pfizer Inc. The product would be available for the US market shortly.

For more details, check out the full story on the link below:

Granules India Secures USFDA Nod For Prazosin Hydrochloride Capsules


Yellow alert in National capital

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News